Vervets are non-human primates that share high genetic homology with humans and develop amyloid beta (Aβ) pathology with aging. We expand current knowledge by examining Aβ pathology, aging, cognition, and biomarker proteomics.
Amyloid immunoreactivity in the frontal cortex and temporal cortex/hippocampal regions from archived vervet brain samples ranging from young adulthood to old age was quantified. We also obtained cognitive scores, plasma samples, and cerebrospinal fluid (CSF) samples in additional animals. Plasma and CSF proteins were quantified with platforms utilizing human antibodies.
We found age-related increases in Aβ deposition in both brain regions. Bioinformatic analyses assessed associations between biomarkers and age, sex, cognition, and CSF Aβ levels, revealing changes in proteins related to immune-related inflammation, metabolism, and cellular processes.
Vervets are an effective model of aging and early-stage Alzheimer’s disease, and we provide translational biomarker data that both align with previous results in humans and provide a basis for future investigations.

We found changes in immune and metabolic plasma biomarkers associated with age and cognition.
Cerebrospinal fluid (CSF) biomarkers revealed changes in cell signaling indicative of adaptative processes.
TNFRSF19 (TROY) and Artemin co-localize with Alzheimer’s disease pathology.
Vervets are a relevant model for translational studies of early-stage Alzheimer’s disease.

If you do not see content above, kindly GO TO SOURCE.
Not all publishers encode content in a way that enables republishing at Neuro.vip.

This post is Copyright: Curran Varma,
Eva Luo,
Gustaf Bostrom,
Praveen Bathini,
Daniela Berdnik,
Tony Wyss‐Coray,
Tingting Zhao,
Xianjun Dong,
Frank R. Ervin,
Amy Beierschmitt,
Roberta M. Palmour,
Cynthia A. Lemere | July 1, 2024

Wiley: Alzheimer’s & Dementia: Table of Contents